3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
58
Prostatic Neoplasms, Castration-Resistant
5
Neoplasm Metastasis
4
Metastatic Castration-resistant Prostate Cancer
4
Prostatic Diseases
3
Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Triple Negative Breast Neoplasms
2
Salivary Gland Neoplasms
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Neoplasms
1
Urogenital Diseases
1
Thrombocytosis
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic Hormone-sensitive Prostate Cancer
1
Interventions
fluciclovine F-18
2
relatlimab
1
pembrolizumab
1
enfortumab vedotin
1
darolutamide
1
Watchful Waiting
1
Transurethral Resection of Prostate
1
Sunitinib
1
Radiotherapy
1
Radiation Dose Hypofractionation
1
Pregnancy Tests
1
Nivolumab
1
Mitomycin
1
Magnetic Resonance Spectroscopy
1
Human Papillomavirus DNA Tests
1
Gemcitabine
1
Fluorouracil
1
Colposcopy
1
Cisplatin
1
Biopsy
1
Acetic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Diseases
×
darolutamide
×
Clear all
NCT07103018
2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1
Recruiting
144 enrolled